


About AC BioScience



- A Swiss biotech company based at the EPFL Innovation Park and Biopôle
- Pioneering new therapies in immuno-oncology and tumor vascular normalisation
- About to start clinical trials with two of three leading-edge cancer drugs
- Multi-billion \$ sales potential
- Top team with complementary skill sets



Andreas Schlaepfer,
Co-founder and CEO, MEcon,
Former SVP and Global
Business Head of Nestlé's
Infant Nutrition Business and
CEO of several of Nestlé's key
markets



Dr. Christian Auclair,
Co-founder and CSO, Emeritus
professor (exceptional class)
and Doctor in Science (PharmD,
PhD) in pharmacology,
molecular oncology and innate
immunity



Dr. Annette Ives,
Director Infectious Diseases,
PhD in Immunology and
Infections



Dr. Camilla Flores,
CMO Oncology, MD, PhD in
Immuno-oncology



Dr. Manale Karam,
Scientific Officer Oncology,
PhD in molecular and cellular
oncology

ACB1801: Aiming to potentiate anti PD-1 therapy efficacy

The thriving immuno-oncology market (est. \$20bn in 2020, CAGR 13%) got a problem:
Efficacy of existing drugs has plateaued (60 to 70% of treated patients are not responders)


ACB1801 (alkaloid in the series of beta-carbolines) – a tumor reversion breakthrough

ACB1801

Actin dynamic remodeling
No cytotoxicity


Recovery of tumor antigenicity

- Increased MHC-1 mediated antigen presentation



Reversion of malignant phenotype

- Rescue of cell-cell adhesion
- Inhibition of cell migration
- Loss of anchorage-independent growth




Normal cells

Malignant cells

Malignant cells + ACB1801

ACB1801 is enhancing the efficacy of anti PD-1 drugs:


+65 % survival rate in melanoma B16-F10 model




ACB1801: Significant Market and Revenue Potential

- TAM : Combination with anti PD-1 drug (US\$ 40 bn by 2026)
- Annual Peak Sales : US\$ 2.2 bn
- Risk adjusted and discounted cash flows $\sum rNPV$: US\$ 245 million
- Expected selling price of license (PoC 2024) : US\$ 510 million


Revenues and gross margins



Probability of success



Fund-raising Milestones



We are seeking

- Financial investors
- Strategic partnerships with pharmaceutical companies

to finance our clinical validation programs



ac-bioscience.com